We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    Thoracentesis | Recruiting, Not yet recruiting, Available Studies | NIH, U.S. Fed

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

This study is currently recruiting participants.
Verified August 2017 by Pierre P. Massion, MD, Vanderbilt-Ingram Cancer Center
Sponsor:
ClinicalTrials.gov Identifier:
NCT00898313
First Posted: May 12, 2009
Last Update Posted: August 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Pierre P. Massion, MD, Vanderbilt-Ingram Cancer Center
  Purpose

RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at molecular predictors of cancer in patients at high risk of lung cancer.


Condition Intervention
Lung Cancer Genetic: comparative genomic hybridization Genetic: gene expression microarray analysis Genetic: proteomic profiling analysis Other: biologic sample preservation procedure Procedure: nasal brushing Procedure: Blood draw Procedure: Urine collection Procedure: sputum sample Procedure: fluorescence bronchoscopy with airway biopsy Procedure: fine needle aspiration of the lung Procedure: thoracentesis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Molecular Predictors of Lung Cancer Behavior

Resource links provided by NLM:


Further study details as provided by Pierre P. Massion, MD, Vanderbilt-Ingram Cancer Center:

Primary Outcome Measures:
  • To quantitate the molecular changes during lung cancer development [ Time Frame: After collection of designated samples ]

    As a part of the study nasal brushing specimens, sputum, blood, urine, and a small amount of other tissue will be collected during standard of care procedures (bronchial epithelial, trans-thoracic fine needle aspiration (FNA) and thoracentesis as part of patient work up.

    Clinical diagnosis is the primary goal of the procedure. All the research specimens are collected after the primary goal of the procedure is met.



Secondary Outcome Measures:
  • Develop a method to diagnose and stage pre-invasive and invasive lesions [ Time Frame: After collection of designated samples ]
    Use of proteomic techniques in the laboratory to find a method of diagnosing lung tissue as benign or malignant rather than relying on invasive open-chest surgery for a diagnosis


Biospecimen Retention:   Samples With DNA
Blood, urine, nasal cells, sputum, bronchal epithelial cells, airway tissue, and lung tissue

Estimated Enrollment: 2000
Study Start Date: December 2003
Estimated Study Completion Date: January 31, 2025
Estimated Primary Completion Date: January 31, 2025 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Sample Collection Genetic: comparative genomic hybridization
Collection of sputum, blood, urine, and a small amount of lung tissue.
Genetic: gene expression microarray analysis
Collection of sputum, blood, urine, and a small amount of lung tissue.
Genetic: proteomic profiling analysis
Collection of sputum, blood, urine, and a small amount of lung tissue.
Other: biologic sample preservation procedure
Collection of sputum, blood, urine, and a small amount of lung tissue.
Procedure: nasal brushing
Using a brush, superficial cells are removed from the nose.
Procedure: Blood draw
Venous blood will be collected
Procedure: Urine collection
Subjects will be asked to provide a urine specimen.
Procedure: sputum sample
Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
Procedure: fluorescence bronchoscopy with airway biopsy
A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
Procedure: fine needle aspiration of the lung
A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
Procedure: thoracentesis
A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.

Detailed Description:

OBJECTIVES:

  • To use fixed lung tissue for histological evaluation and fresh tissue samples for molecular studies to study DNA, RNA, and protein abnormalities in lung preneoplastic and neoplastic lesions.
  • To use proteomic techniques, including matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS), to develop a method of diagnosing and staging both pre-invasive and invasive lesions, using less invasive methods.

OUTLINE: Blood, urine, nasal cell, and sputum samples are collected. Lung tissue samples are also collected using fluorescence bronchoscopy and epithelial cell collection.

Samples are studied by genetic and proteomic analyses, including comparative genomic hybridization, expression microarray, and protein profiling.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
People who may have lung cancer.
Criteria

Inclusion Criteria:

-All adults referred to Vanderbilt Medical Center, Veterans Administration Medical Center, St. Thomas Hospital and Meharry Medical Center for evaluation of signs or symptoms of lung cancer.

Exclusion Criteria:

  • Inability to provide informed consent
  • Minors
  • Pregnant women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00898313


Contacts
Contact: Vanderbilt Ingram Clinical Trials Information Program 1-800-811-8480

Locations
United States, Tennessee
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37212
Contact: VICC Clinical Trials Information Program    800-811-8480    cip@vanderbilt.edu   
Principal Investigator: Pierre Massion, MD         
Veterans Affairs Medical Center - Nashville Recruiting
Nashville, Tennessee, United States, 37212
Contact: Research Office    615-873-8066      
Contact: Rena Burns, RN    (615) 873-7658    Rena.Burns@va.gov   
Principal Investigator: Pierre Massion, MD         
Sponsors and Collaborators
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
Investigators
Study Chair: Pierre P. Massion, MD Vanderbilt-Ingram Cancer Center
  More Information

Additional Information:
Responsible Party: Pierre P. Massion, MD, Associate Professor of Medicine (Allergy, Pulmonary & Critical Care) and Cancer Biology; Pulmonary and Critical Care Medicine Doctor, Vanderbilt-Ingram Cancer Center
ClinicalTrials.gov Identifier: NCT00898313     History of Changes
Other Study ID Numbers: VICC THO 0398
P30CA068485 ( U.S. NIH Grant/Contract )
First Submitted: May 9, 2009
First Posted: May 12, 2009
Last Update Posted: August 23, 2017
Last Verified: August 2017

Keywords provided by Pierre P. Massion, MD, Vanderbilt-Ingram Cancer Center:
lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases